Christopher Rohde
Overview
Explore the profile of Christopher Rohde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rohde C, Williams L, Berk M, Ostergaard S
Acta Neuropsychiatr
. 2025 Mar;
:1-23.
PMID: 40062740
Objectives: Selective serotonin reuptake inhibitors (SSRIs) have been associated with increased risk of osteoporosis, and sertraline may be more potent than citalopram in this regard. Here, target trial emulation was...
2.
Verdoux H, Bittner R, Hasan A, Qubad M, Wagner E, Lepetit A, et al.
Eur Psychiatry
. 2025 Jan;
68(1):e17.
PMID: 39788917
The European Clozapine Task Force is a group of psychiatrists and pharmacologists practicing in 18 countries under European Medicines Agency (EMA) regulation, who are deeply concerned about the underuse of...
3.
Hojlund M, Kohler-Forsberg O, Gregersen A, Rohde C, Mellentin A, Anhoj S, et al.
Lancet Psychiatry
. 2024 Nov;
11(12):975-989.
PMID: 39547246
Background: Antipsychotic polypharmacy remains a clinical reality, despite an increased risk of adverse events and little evidence of additional efficacy compared with antipsychotic monotherapy. In this systematic review and meta-analysis,...
4.
Ishtiak-Ahmed K, Rohde C, Kohler-Forsberg O, Sparle Christensen K, Gasse C
Int J Geriatr Psychiatry
. 2024 Nov;
39(11):e70006.
PMID: 39487699
Objective: This study aimed to describe depression treatment patterns, identify unique trajectory groups using a group-based trajectory approach, and explore associated social determinants in older adults undergoing first-time depression treatment...
5.
Madsen N, Sorensen M, Danielsen A, Hojlund M, Rohde C, Kohler-Forsberg O
Acta Psychiatr Scand
. 2024 Oct;
151(1):69-80.
PMID: 39379169
Background: Antipsychotics increase the risk of developing diabetes, but clinical trials are not generalizable with short follow-up, while observational studies often lack important information, particularly hemoglobin A1c (HbA1c). Methods: We...
6.
Thomsen R, Salagre E, Rohde C, Ostergaard S
Bipolar Disord
. 2024 Aug;
26(8):785-792.
PMID: 39135138
Objectives: Electroconvulsive therapy (ECT) is an effective treatment for bipolar disorder, but relapse following a successful ECT series is common. We aimed to identify clinical and sociodemographic characteristics associated with...
7.
Rohde C, Hieronymus F, Ostergaard S
Acta Psychiatr Scand
. 2024 Jul;
150(4):198-208.
PMID: 38994727
Background: The comparative effectiveness of selective serotonin reuptake inhibitors (SSRIs) has been subjected to relatively little research. However, a recent study based on target trial emulation suggested that sertraline may...
8.
Rohde C, Ostergaard S, Jefsen O
Am J Psychiatry
. 2024 Jul;
181(7):630-638.
PMID: 38946271
Objective: Antidepressants are commonly used to treat bipolar depression but may increase the risk of mania. The evidence from randomized controlled trials, however, is limited by short treatment durations, providing...
9.
Jacobsen S, Kohler-Forsberg O, Rohde C
Schizophr Res
. 2024 Jun;
270:231-234.
PMID: 38936114
No abstract available.
10.
Kohler-Forsberg O, Hojlund M, Rohde C, Kemp A, Gregersen A, Mellentin A, et al.
Schizophr Res
. 2024 Jun;
270():135-143.
PMID: 38908279
Background: Antipsychotic polypharmacy (APP) is frequent but evidence-based guidelines on reducing APP to antipsychotic monotherapy (APM) are sparse. We aimed to systematically review clinical interventions randomizing patients to reducing APP...